MULTIMODAL SPECTROSCOPIC EVALUATION OF CERVICAL CANCER

宫颈癌的多模态光谱评估

• 批准号: 6298487
• 负责人: Shabbir Bakir Bambot
• 金额: $ 12.96万
• 依托单位: GUIDED THERAPEUTICS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-08-01 至 2002-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298487
• 关键词: bioengineering /biomedical engineering; bioimaging /biomedical imaging; biomedical equipment development; cervix neoplasms; diagnosis design /evaluation; early diagnosis; fiber optics; fluorescence spectrometry; neoplasm /cancer diagnosis; noninvasive diagnosis; reflection spectrometry

DESCRIPTION (Verbatim from the Applicant's Abstract): Cervical cancer is the second most common cause of cancer in women worldwide and the leading cause of cancer related mortality in women in developing countries. We have developed real time non-invasive point-of-care devices to detect early cancerous conditions of cervix. Our preliminary analyses on data collected from a total of 133 patients and have shown promising results. We are continuing to collect data and will include the entire data set into the analysis as part of our phase I objective. Given our limited data set, however, it is not possible to project any definite performance benchmark. We will propose this task to the training and validation phase in a Phase 2 proposal. For the present we want to analyze the data for the purpose of determining the optimum clinical device for the validation phase. To support data accrual in the validation phase we will make multiple clones of this device for deployment in a multicenter clinical trial. The objective of the data analysis is to arrive at this validation device by simplifying and consolidating the complexity and the many features built into each prototype. This will also reduce the possibility of overtraining by reducing the number of parameters we build into our algorithm. PROPOSED COMMERCIAL APPLICATION: The product of this research will be a prototype device capable to spectroscopically detecting and/or diagnosing cervical cancer. Our device has, upon commercialization, the potential to replace or aid the current Pap test as well as to replace the current methods of colposcopy, biopsy and histology. The target physician group for the cervical application is the Ob-Gyn segment. It is estimated that there are at least 30,000 physicians in this segment and upwards of $6 billion spent each year in the US on cervical disease.

描述（来自申请人摘要的逐字）：宫颈癌是一种常见的癌症。 全球女性癌症的第二大常见原因， 发展中国家妇女的癌症相关死亡率。我们已经开发 用于检测早期癌症的真实的时间非侵入性护理点设备 宫颈的条件。我们初步分析了从总共收集的数据， 133例患者，并显示出有希望的结果。我们将继续收集 数据，并将整个数据集纳入分析，作为我们 第一阶段目标。然而，鉴于我们有限的数据集， 制定明确的业绩基准。我们将把这项任务提交给 培训和验证阶段。目前我们想 分析数据，以确定最佳临床器械， 验证阶段。为了支持验证阶段的数据累积，我们将 制作该器械的多个克隆，以便在多中心临床试验中展开 审判数据分析的目的是进行验证 通过简化和整合复杂性和许多功能， 内置在每个原型中。这也将减少 通过减少我们在算法中构建的参数数量来避免过度训练。 拟定商业应用： 这项研究的产品将是一个原型设备，能够光谱检测 和/或诊断宫颈癌。 我们的设备在商业化后， 取代或辅助目前的巴氏试验以及取代目前的阴道镜检查方法， 活检和组织学。 宫颈应用的目标医生群体是妇产科医生 片段 据估计，这一领域至少有30，000名医生， 美国每年花在宫颈疾病上的60亿美元。